ArticleBMJ open gastroenterology2026
Aetiology and outcomes of emergency admissions for chronic liver disease in England, 2012-2019: a national cohort study using administrative data.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic liver disease (CLD) deaths in the UK have risen fivefold since 1970. People with CLD often present with advanced disease. We investigated trends in aetiology, care, and outcomes of patients with a first emergency admission (FEA) for CLD in England.
methodsIn a retrospective cohort study, we analysed national administrative data of hospital admissions (Hospital Episode Statistics Admitted Patient Care data) to identify patients with a FEA for CLD between April 2012 and March 2019. We used negative binomial, logistic and proportional hazards regression to explore time trends in admission numbers according to population size, demographics, aetiology, readmissions, mortality, transplantation, and the treating clinicians' specialty.
resultsThere were 83 527 FEAs for CLD during the 7-year study period, with numbers increasing each year. There was no evidence of a time trend when population size was taken into account (p=0.51). Of these FEAs, 65.3% had alcohol-related aetiologies. The proportion of FEAs with viral aetiologies decreased (7.3% in 2012-2014 vs 5.6% in 2016-2019; p<0.001) and metabolic dysfunction-associated steatotic liver disease (MASLD) increased (5.8-11.3%; p<0.001), respectively. Mortality within 30 days was 17.3% and 37.3% within 1 year. 1-year all-cause mortality improved over the study period (2012-2014 vs 2016-2018 adjusted HR 0.92 (95% CI 0.90 to 0.95)) but 30-day readmission rate increased (1.04 (95% CI 1.00 to 1.09)). Over 40% of patients did not receive care from a hepatologist/gastroenterologist during the FEA and <1% received liver transplant within 1 year.
conclusionThe number of patients with FEA for CLD increased in line with population size between 2012 and 2019. The dominant aetiology was alcohol-related, but the proportion with MASLD nearly doubled over the study period. There were improvements in survival, but over a third of patients died within a year, and over a third of hospital survivors were readmitted. Many patients did not receive specialist inpatient care or evidence-based interventions, suggesting opportunities to improve survival and resource use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.